Literature DB >> 16046631

Influence of the N-terminal domain on the aggregation properties of the prion protein.

Kristen N Frankenfield1, Evan T Powers, Jeffery W Kelly.   

Abstract

Prion diseases appear to be caused by the aggregation of the cellular prion protein (PrP(C)) into an infectious form denoted PrP(Sc). The in vitro aggregation of the prion protein has been extensively investigated, yet many of these studies utilize truncated polypeptides. Because the C-terminal portion of PrP(Sc) is protease-resistant and retains infectivity, it is assumed that studies on this fragment are most relevant. The full-length protein can be distinguished from the truncated protein because it contains a largely structured, alpha-helical, C-terminal region in addition to an N terminus that is unstructured in the absence of metal ion binding. Herein, the in vitro aggregation of a truncated portion of the prion protein (PrP 90-231) and a full-length version (PrP 23-231) were compared. In each case, concentration-dependent aggregation was analyzed to discern whether it proceeds by a nucleation-dependent pathway. Both protein constructs appear to aggregate via a nucleated polymerization with a small nucleus size, yet the later steps differ. The full-length protein forms larger aggregates than the truncated protein, indicating that the N terminus may mediate higher-order aggregation processes. In addition, the N terminus has an influence on the assembly state of PrP before aggregation begins, causing the full-length protein to adopt several oligomeric forms in a neutral pH buffer. Our results emphasize the importance of studying the full-length protein in addition to the truncated forms for in vitro aggregation studies in order to make valid hypotheses about the mechanisms of prion aggregation and the distribution of aggregates in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046631      PMCID: PMC2279327          DOI: 10.1110/ps.051434005

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  44 in total

1.  Folding of prion protein to its native alpha-helical conformation is under kinetic control.

Authors:  I V Baskakov; G Legname; S B Prusiner; F E Cohen
Journal:  J Biol Chem       Date:  2001-04-16       Impact factor: 5.157

2.  Aggregation and fibrillization of the recombinant human prion protein huPrP90-231.

Authors:  W Swietnicki; M Morillas; S G Chen; P Gambetti; W K Surewicz
Journal:  Biochemistry       Date:  2000-01-18       Impact factor: 3.162

3.  N-terminal truncation of prion protein affects both formation and conformation of abnormal protease-resistant prion protein generated in vitro.

Authors:  V A Lawson; S A Priola; K Wehrly; B Chesebro
Journal:  J Biol Chem       Date:  2001-07-20       Impact factor: 5.157

4.  Pathway complexity of prion protein assembly into amyloid.

Authors:  Ilia V Baskakov; Giuseppe Legname; Michael A Baldwin; Stanley B Prusiner; Fred E Cohen
Journal:  J Biol Chem       Date:  2002-03-23       Impact factor: 5.157

Review 5.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Authors:  Byron Caughey; Peter T Lansbury
Journal:  Annu Rev Neurosci       Date:  2003-04-09       Impact factor: 12.449

6.  A cellular gene encodes scrapie PrP 27-30 protein.

Authors:  B Oesch; D Westaway; M Wälchli; M P McKinley; S B Kent; R Aebersold; R A Barry; P Tempst; D B Teplow; L E Hood
Journal:  Cell       Date:  1985-04       Impact factor: 41.582

7.  On the mechanism of alpha-helix to beta-sheet transition in the recombinant prion protein.

Authors:  M Morillas; D L Vanik; W K Surewicz
Journal:  Biochemistry       Date:  2001-06-12       Impact factor: 3.162

Review 8.  Prion diseases of humans and animals: their causes and molecular basis.

Authors:  J Collinge
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

9.  Formation of critical oligomers is a key event during conformational transition of recombinant syrian hamster prion protein.

Authors:  Fabian Sokolowski; Andreas Johannes Modler; Ralf Masuch; Dietrich Zirwer; Michael Baier; Gudrun Lutsch; David Alan Moss; Klaus Gast; Dieter Naumann
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

10.  The octapeptide repeats in mammalian prion protein constitute a pH-dependent folding and aggregation site.

Authors:  Ralph Zahn
Journal:  J Mol Biol       Date:  2003-11-28       Impact factor: 5.469

View more
  28 in total

1.  The kinetics of nucleated polymerizations at high concentrations: amyloid fibril formation near and above the "supercritical concentration".

Authors:  Evan T Powers; David L Powers
Journal:  Biophys J       Date:  2006-04-07       Impact factor: 4.033

2.  Use of thermolysin in the diagnosis of prion diseases.

Authors:  Jonathan P Owen; Ben C Maddison; Garry C Whitelam; Kevin C Gough
Journal:  Mol Biotechnol       Date:  2007-02       Impact factor: 2.695

3.  Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation.

Authors:  Evan T Powers; David L Powers
Journal:  Biophys J       Date:  2007-09-21       Impact factor: 4.033

4.  Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity.

Authors:  Kenji Usui; John D Hulleman; Johan F Paulsson; Sarah J Siegel; Evan T Powers; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

5.  Cyclin-dependent kinase 5 phosphorylation of familial prion protein mutants exacerbates conversion into amyloid structure.

Authors:  Raphaël Rouget; Gyanesh Sharma; Andréa C LeBlanc
Journal:  J Biol Chem       Date:  2015-01-08       Impact factor: 5.157

6.  The crystal structure of an octapeptide repeat of the prion protein in complex with a Fab fragment of the POM2 antibody.

Authors:  Mridula Swayampakula; Pravas Kumar Baral; Adriano Aguzzi; Nat N V Kav; Michael N G James
Journal:  Protein Sci       Date:  2013-05-31       Impact factor: 6.725

Review 7.  Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases.

Authors:  Anna Villar-Piqué; Matthias Schmitz; Niccolò Candelise; Salvador Ventura; Franc Llorens; Inga Zerr
Journal:  Mol Neurobiol       Date:  2018-02-10       Impact factor: 5.590

8.  The octarepeat region of the prion protein is conformationally altered in PrP(Sc).

Authors:  Alice Y Yam; Carol Man Gao; Xuemei Wang; Ping Wu; David Peretz
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

9.  Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans.

Authors:  Shaoman Yin; Nancy Pham; Shuiliang Yu; Chaoyang Li; Poki Wong; Binggong Chang; Shin-Chung Kang; Emiliano Biasini; Po Tien; David A Harris; Man-Sun Sy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-24       Impact factor: 11.205

10.  Prion protein self-peptides modulate prion interactions and conversion.

Authors:  Alan Rigter; Jan Priem; Drophatie Timmers-Parohi; Jan P M Langeveld; Fred G van Zijderveld; Alex Bossers
Journal:  BMC Biochem       Date:  2009-11-30       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.